Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating acute lymphoblastic leukemia.

PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens to compare how well they work in treating young patients with acute lymphoblastic leukemia.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universitätsklinikum Hamburg-Eppendorf
• Treatments: 6-Mercaptopurine; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Doxorubicin; Liposomal doxorubicin; Mercaptopurine; Methotrexate; Pegaspargase; Prednisolone; Teniposide; Thioguanine; Vincristine

Criteria

DISEASE CHARACTERISTICS:

• Diagnosed with acute B-precursor or T-cell acute lymphoblastic leukemia (ALL)

• Meets 1 of the following risk criteria:

• Low-risk disease, defined by any of the following:

• WBC < 25/nL

• B-precursor ALL

• Excluding pro-B ALL

• High-risk disease, defined by any of the following:

• WBC ≥ 25/nL

• T-cell ALL or pro-B ALL

• Chromosomal translocation 4/11

PATIENT CHARACTERISTICS:

• Not specified

PRIOR CONCURRENT THERAPY:

• More than 7 days since prior therapy with steroids, vincristine, or daunorubicin hydrochloride

• More than 7 days since prior cytotoxic therapy